Teriparatide biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Drug Profile

Teriparatide biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Alternative Names: Recombinant human parathyroid hormone 1-34 - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical; rhPTH1-34 - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Osteoporosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Osteoporosis in China (SC)
  • 14 May 2015 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans to submit a phase II application for Osteoporosis to Chinese SFDA in second half of 2015
  • 24 Mar 2015 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase I trial in Osteoporosis in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top